Tokyo Tape
Sign in
← Torii Pharmaceutical

Annual report

4551.TEDINET S100VH2F
Period2024-01-01 → 2024-12-31
Filed2025-03-27
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 89
MetricValuePeriodScopeSource row
Revenue¥60.4bn2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥54.6bn2023-01-01 → 2023-12-31StandaloneNet sales
Revenue¥48.9bn2022-01-01 → 2022-12-31dStandaloneNet sales (5-year summary)
Revenue¥47.0bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Revenue¥41.7bn2020-01-01 → 2020-12-31dStandaloneNet sales (5-year summary)
Operating income¥6.8bn2024-01-01 → 2024-12-31StandaloneOperating income
Operating income¥5.0bn2023-01-01 → 2023-12-31StandaloneOperating income
Ordinary income¥6.9bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income¥5.3bn2023-01-01 → 2023-12-31StandaloneOrdinary income
Ordinary income¥5.5bn2022-01-01 → 2022-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥4.8bn2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income¥5.0bn2020-01-01 → 2020-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax¥6.7bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Profit before tax¥5.6bn2023-01-01 → 2023-12-31StandaloneIncome before income taxes
Net income¥5.0bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income¥4.1bn2023-01-01 → 2023-12-31StandaloneProfit loss
Net income¥3.9bn2022-01-01 → 2022-12-31dStandaloneNet income loss (5-year summary)
Net income¥3.4bn2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Net income¥3.5bn2020-01-01 → 2020-12-31dStandaloneNet income loss (5-year summary)
Total assets¥140.7bnat 2024-12-31StandaloneAssets
Total assets¥133.4bnat 2023-12-31StandaloneAssets
Total assets¥133.7bnat 2022-12-31dStandaloneTotal assets (5-year summary)
Total assets¥130.8bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total assets¥126.0bnat 2020-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥19.1bnat 2024-12-31StandaloneLiabilities
Total liabilities¥13.3bnat 2023-12-31StandaloneLiabilities
Net assets / equity¥121.5bnat 2024-12-31StandaloneNet assets
Net assets / equity¥120.1bnat 2023-12-31StandaloneNet assets
Net assets / equity¥119.2bnat 2022-12-31dStandaloneNet assets
Net assets / equity¥117.0bnat 2021-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥115.1bnat 2020-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥3.3bnat 2024-12-31StandaloneCash and deposits
Cash and deposits¥5.0bnat 2023-12-31StandaloneCash and deposits
Cash & equivalents¥30.8bnat 2024-12-31StandaloneCash and cash equivalents
Cash & equivalents¥34.7bnat 2023-12-31StandaloneCash and cash equivalents
Cash & equivalents¥45.4bnat 2022-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥58.4bnat 2021-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥61.6bnat 2020-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow¥3.6bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥3.1bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow¥2.4bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥156m2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥3.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow−¥3.6bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥3.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow−¥13.7bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥7.6bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow−¥3.9bn2024-01-01 → 2024-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥3.8bn2023-01-01 → 2023-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥1.7bn2022-01-01 → 2022-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.5bn2021-01-01 → 2021-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.4bn2020-01-01 → 2020-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥179.382024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥146.62023-01-01 → 2023-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥140.392022-01-01 → 2022-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥120.132021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥124.472020-01-01 → 2020-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥124.462020-01-01 → 2020-12-31dStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥1202024-01-01 → 2024-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1202023-01-01 → 2023-12-31StandaloneDividend paid per share (5-year summary)
Dividend per share¥1002022-01-01 → 2022-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482021-01-01 → 2021-12-31dStandaloneDividend paid per share (5-year summary)
Dividend per share¥482020-01-01 → 2020-12-31dStandaloneDividend paid per share (5-year summary)
Net assets per share¥4,323.33at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,274.45at 2023-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥4,243.08at 2022-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,165.38at 2021-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥4,097.55at 2020-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio86.4%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio90.0%at 2023-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio89.2%at 2022-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio89.5%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio91.3%at 2020-12-31dStandaloneEquity to asset ratio (5-year summary)
ROE4.2%2024-01-01 → 2024-12-31StandaloneRate of return on equity (5-year summary)
ROE3.4%2023-01-01 → 2023-12-31StandaloneRate of return on equity (5-year summary)
ROE3.3%2022-01-01 → 2022-12-31dStandaloneRate of return on equity (5-year summary)
ROE2.9%2021-01-01 → 2021-12-31dStandaloneRate of return on equity (5-year summary)
ROE3.1%2020-01-01 → 2020-12-31dStandaloneRate of return on equity (5-year summary)
Shares issued28,800,000at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2023-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2022-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued28,800,000at 2020-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees592at 2024-12-31StandaloneNumber of employees
Employees583at 2023-12-31StandaloneNumber of employees
Employees563at 2022-12-31dStandaloneNumber of employees
Employees560at 2021-12-31dStandaloneNumber of employees
Employees568at 2020-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 1
SegmentItemPeriodValue
Pharmaceutical Businessreportable segmentemployeesat 2024-12-31592 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 974
ItemContextValueUnit
Purchase of short term investment securities inv cfCurrentYearDuration_NonConsolidatedMember-10007000000JPY
Proceeds from sales and redemption of securities inv cfPrior1YearDuration_NonConsolidatedMember16500000000JPY
Proceeds from sales and redemption of securities inv cfCurrentYearDuration_NonConsolidatedMember17000000000JPY
Purchase of property plant and equipment inv cfPrior1YearDuration_NonConsolidatedMember-162000000JPY
Purchase of property plant and equipment inv cfCurrentYearDuration_NonConsolidatedMember-152000000JPY
Proceeds from sales of property plant and equipment inv cfPrior1YearDuration_NonConsolidatedMember0JPY
Proceeds from sales of property plant and equipment inv cfCurrentYearDuration_NonConsolidatedMember－JPY
Purchase of intangible assets inv cfPrior1YearDuration_NonConsolidatedMember-54000000JPY
Purchase of intangible assets inv cfCurrentYearDuration_NonConsolidatedMember-28000000JPY
Purchase of investment securities inv cfPrior1YearDuration_NonConsolidatedMember-17588000000JPY
Purchase of investment securities inv cfCurrentYearDuration_NonConsolidatedMember-21065000000JPY
Proceeds from sales and redemption of investment securities inv cfPrior1YearDuration_NonConsolidatedMember6527000000JPY
Proceeds from sales and redemption of investment securities inv cfCurrentYearDuration_NonConsolidatedMember12500000000JPY
Other net inv cfPrior1YearDuration_NonConsolidatedMember－JPY
Other net inv cfCurrentYearDuration_NonConsolidatedMember-1817000000JPY
Net cash provided by used in investment activitiesPrior1YearDuration_NonConsolidatedMember-3779000000JPY
Net cash provided by used in investment activitiesCurrentYearDuration_NonConsolidatedMember-3571000000JPY
Purchase of treasury stock fin cfPrior1YearDuration_NonConsolidatedMember-0JPY
Purchase of treasury stock fin cfCurrentYearDuration_NonConsolidatedMember-2000000JPY
Cash dividends paid fin cfPrior1YearDuration_NonConsolidatedMember-3540000000JPY
Cash dividends paid fin cfCurrentYearDuration_NonConsolidatedMember-3654000000JPY
Repayments of lease obligations fin cfPrior1YearDuration_NonConsolidatedMember-293000000JPY
Repayments of lease obligations fin cfCurrentYearDuration_NonConsolidatedMember-287000000JPY
Net cash provided by used in financing activitiesPrior1YearDuration_NonConsolidatedMember-3835000000JPY
Net cash provided by used in financing activitiesCurrentYearDuration_NonConsolidatedMember-3944000000JPY
Net increase decrease in cash and cash equivalentsPrior1YearDuration_NonConsolidatedMember-10738000000JPY
Net increase decrease in cash and cash equivalentsCurrentYearDuration_NonConsolidatedMember-3876000000JPY
Cash and cash equivalentsPrior2YearInstant_NonConsolidatedMember45420000000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember34681000000JPY
Cash and cash equivalentsPrior1YearInstant_NonConsolidatedMember34681000000JPY
Cash and cash equivalentsCurrentYearInstant_NonConsolidatedMember30805000000JPY
Write downs of inventoriesPrior1YearDuration_NonConsolidatedMember74000000JPY
Write downs of inventoriesCurrentYearDuration_NonConsolidatedMember-252000000JPY
Research and development expenses sgaPrior1YearDuration_NonConsolidatedMember3490000000JPY
Research and development expenses sgaCurrentYearDuration_NonConsolidatedMember2824000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)有価証券報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2025-03-27
Fiscal year cover pageFilingDateInstant
Original text (Japanese)第133期(自　2024年１月１日　至　2024年12月31日)
Company name cover pageFilingDateInstant
Original text (Japanese)鳥居薬品株式会社
Company name in english cover pageFilingDateInstantTORII PHARMACEUTICAL CO., LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　　近藤　紳雅
Address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町三丁目４番１号
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03-3231-6811（代表）
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)経営企画部長　　萩原　知仁
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都中央区日本橋本町三丁目４番１号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03-3231-6811（代表）
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)経営企画部長　　萩原　知仁
Place for public inspection cover page (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2023-12-31pass
balance sheet identitynon_consolidated 2024-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2022-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · operating cash flownon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · operating cash flownon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2023-01-01/2023-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · total assetsnon_consolidated 2023-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass